Bentley's Spanish units get approval for tamulosin
US specialty drugmaker Bentley Pharmaceuticals says that its subsidiaries, Laboratorios Davur and Laboratorios Rimafar, have received product approval for tamulosin from the Spanish Ministry of Health. Another Bentley affiliate, Laboratorios Belmac, also received approval for a branded generic equivalent of tamulosin under the trade name Vetevel.
Tamulosin is the generic equivalent to Boehringer Ingelheim's product marketed under the trade name Urolosin in Spain and Flomax in the USA. The drug is used in the treatment of benign prostatic hyperplasia and related bladder outlet obstruction. According to IMS Health, the annual market size in Spain for tamulosin is around $93.0 million and grew 6.4% over the trailing12 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze